A compound heterozygous variant of PLA2G6 (c.1634A > G, c.991G > T) was detected, which is the only mutation in a recessive gene detected in our study, aside from PRKN. The 33-year-old patient suffered from dystonia of the left foot, and developed dyskinesia after two years despite responding well to levodopa in early treatment, which was consistent with the clinical manifestation of dystonia-Parkinson’s syndrome caused by PLA2G6 (Paisan-Ruiz et al., 2009). This evidence concerns the gene PLA2G6 and drug-induced dyskinesia.